As the new year dawns, we want to take a moment to thank each of you for being part of our journey. Whether you’ve followed us, supported our work, or shared our mission with others, your encouragement means the world to us.
At Opticyte, we believe that innovation can save lives—and that belief is stronger than ever as we reflect on the progress we’ve made this year. From advancing our groundbreaking VitalO₂ technology to bringing awareness to the urgent need for equitable, life-saving innovation in oxygen monitoring, 2024 has been a year of impact and growth.
Sepsis remains a leading cause of death in U.S. hospitals, claiming hundreds of thousands of lives annually. But thanks to your support, we’re closer than ever to changing that story. Our mission to detect sepsis earlier, address health inequities, and empower clinicians with real-time insights wouldn’t be possible without you.
As we look ahead to 2025, we’re filled with hope. Hope for the lives that can be saved. Hope for a future where no family loses a loved one to sepsis or other causes of organ failure. And hope that, together, we can make a meaningful difference in healthcare.
We invite you to help us continue this vital work by sharing our campaign with your network or contributing to our StartEngine campaign if you haven’t already. Every action brings us closer to achieving our vision of better outcomes for patients everywhere. Here’s the link to learn more: https://www.startengine.com/offering/opticyte
From all of us at Opticyte, we wish you a joyful holiday season and a bright new year filled with health and hope.
With gratitude,
Lori and the Opticyte Team
This Reg CF offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.